Isomorphic Labs Announces First AI-Designed Drug to Enter Clinical Trials by Year-End

Google's first AI-designed drug is about to enter clinical trials, and the prototype of AI assistant Project Astra is expected to be launched within the year.

According to the UK's Financial Times, Demis Hassabis, founder of Isomorphic Labs, a drug research and development startup under Alphabet, Google's parent company, stated,The company plans to push its first AI-designed drug into clinical trials by the end of this year.

"We are researching major disease areas such as oncology, cardiovascular diseases, and neurodegenerative diseases, and expect to launch our first drug by the end of this year."

Hassabis pointed out,Traditional drug development usually takes 5 to 10 years, but with the help of AI technology, this process could be accelerated 10 times."This will be a huge revolution in the field of human health."

Former U.S. Treasury Secretary Larry Summers once commented:

"We are at a moment of 'amazing technological possibilities,' where we might see the release of a new miracle drug like Wegovy every few years. AI is to the Internet what computers are to calculators."

In addition to drug development, Hassabis also revealed the latest progress on other AI projects at Google. He stated,Google AI Assistant Prototype Project Astra May Be Released to Consumers Later This Year。"Billions" of AI agents are expected to emerge within the next three years, reshaping the architecture of the internet.

Hassabis believes that, despite the "hype" on social media about AGI being just around the corner,But it will take another 5 to 10 years to achieve true AGI.

Isomorphic Labs, established in 2021 as a spin-off from Google's AI research division DeepMind, remains wholly owned by Alphabet. The company’s potential has drawn significant attention from several large pharmaceutical enterprises, which aim to reduce costs and enhance the efficiency of the costly drug development process through collaboration.

Previously, Hassabis revealed that his team is collaborating with Eli Lilly and Novartis on six drug development projects.

Source: Wall Street News